Post-market data collection without overburdening participants

The trial is over. Regulatory approval has landed. But the data requirements? Those carry on, sometimes for years.

Post-market studies are a different beast. Participants are no longer in a controlled setting with coordinators chasing them. They're at home, living their lives, using a product they may not think much about. Some have been using it for months. Some just started. Many don't fully realise they're still contributing to research.

The challenge is real: how do you collect meaningful data from people whose only job is to get on with their day? Here's how the best post-market programmes handle it.

01. Lower the entry threshold

Every additional tap, scroll, or form field is a reason to disengage. In a clinical trial, participants might tolerate longer sessions because the study is the focus. Post-market, it's background noise. That means SMS or email surveys that take under a minute, app check-ins with pre-filled defaults from last time, and passive data collection where the participant has genuinely opted in. If it doesn't fit into a 30-second gap between tasks, some participants will never do it consistently.

02. Rethink what "engagement" looks like

In a trial, a coordinator spots disengagement and acts. Post-market, that layer disappears, and the system needs to carry more of the load. That means every touchpoint has to work harder: messages that feel personal rather than automated, acknowledgements after completion rather than silence, and a gentle nudge after a missed week rather than a firm reminder after 24 hours. Post-market participants aren't dropping out, they're drifting. The difference matters. Drift can be corrected. Dropout often can't.

03. Collect less, but with more intent

The instinct is to ask more questions while you still have access. Resist it. A short, consistent question answered reliably for 18 months is worth far more than a detailed diary that tails off after six weeks. Focus on the signals that genuinely inform safety monitoring or real-world performance:

• Is the product being used as intended?
• Are there unexpected side effects or symptom changes?
• Has anything shifted since the last check-in?

That's usually enough, and it's almost certainly more than you'd get from a 20-item monthly questionnaire.

04. Design for life getting in the way

People travel. They change phones. They get ill. They forget. A post-market system that can't handle a month-long gap without collapsing isn't fit for purpose. Build for it explicitly: re-entry without friction after an absence, contact updates that don't require a support call, and optional pauses that don't trigger exclusion. The participant who comes back after six weeks of silence is still valuable. Don't make it feel like a penalty to return.

05. Close the loop

Most participants are curious about what happened. Not in a detailed clinical sense, but in a human one. Did their contribution matter? Focus group research with patients who'd received implanted cardiac and vascular devices found this desire is genuine and specific, not a vague nicety: patients wanted post-procedural information about their own device and a designated plan for longitudinal follow-up, but the same research found they often lacked trust and perceived real risk in how broadly that information might be shared. That's a useful distinction for post-market communication generally. Participants don't just want to be told something happened with their data. They want to understand who sees it, why, and what plan exists if something needs to be flagged.

You don't need to share blinded results. But you can share participation rates across the programme, a note that findings are being reviewed by a safety board, or a summary when the study concludes, delivered in a way that's honest about who else sees that information and why.

Post-market relationships are quieter than trial relationships. But they don't have to be one-way.